Compare UPWK & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPWK | SRPT |
|---|---|---|
| Founded | 2013 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.3B |
| IPO Year | 2018 | 1997 |
| Metric | UPWK | SRPT |
|---|---|---|
| Price | $20.27 | $23.10 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 29 |
| Target Price | $22.38 | ★ $26.23 |
| AVG Volume (30 Days) | 2.3M | ★ 2.9M |
| Earning Date | 02-11-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 179.51 | N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | $780,858,000.00 | ★ $2,413,715,000.00 |
| Revenue This Year | $4.30 | $13.72 |
| Revenue Next Year | $6.25 | N/A |
| P/E Ratio | $11.76 | ★ N/A |
| Revenue Growth | 2.50 | ★ 47.15 |
| 52 Week Low | $11.13 | $10.42 |
| 52 Week High | $22.32 | $128.75 |
| Indicator | UPWK | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 51.28 | 61.68 |
| Support Level | $19.75 | $20.86 |
| Resistance Level | $21.14 | $22.00 |
| Average True Range (ATR) | 0.74 | 1.00 |
| MACD | -0.14 | 0.11 |
| Stochastic Oscillator | 47.30 | 78.57 |
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with skilled independent professionals. The company develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to clients.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.